Inhibition of p85, the non-catalytic subunit of phosphatidylinositol 3-kinase, exerts potent antitumor activity in human breast cancer cells (290 visite)
Cell Death & (ISSN: 2041-4889, 2041-4889electronic), 2012; 3(12): N/D-N/D.
Tipo di articolo: Journal Article, Abstract, Conference,
Impact factor: 6.044, Impact factor a 5 anni: 6.044
Url: http://www.scopus.com/inward/record.url?eid=2-s2.0-84871250346&partnerID=40&md5=bd670025334313e76f1c52cd79ff9401
Parole chiave: Breast Cancer, Cell Signaling, Growth Factors And Receptors, Oncogenes, Tumor Promotion And Progression, Epidermal Growth Factor Receptor 2, Insulin Receptor Substrate 1, Liposome, Mitogen Activated Protein Kinase 1, P 1257, Phosphatidylinositol 3 Kinase, Phosphatidylinositol 3 Kinase Inhibitor, Phosphopeptide 1257, Protein P85, Trastuzumab, Unclassified Drug, Animal Cell, Animal Experiment, Animal Model, Animal Tissue, Antineoplastic Activity, Apoptosis, Article, Cancer Cell Culture, Cell Death, Cell Proliferation, Controlled Study, Drug Efficacy, Electroporation, Enzyme Activity, Enzyme Inhibition, Enzyme Phosphorylation, Female, Gene Overexpression, Human, Human Cell, Human Tissue, In Vitro Study, In Vivo Gene Transfer, Mouse, Nonhuman, Priority Journal, Protein Expression, Protein Function, Protein Protein Interaction, Protein Targeting, Treatment Response, Tumor Growth, Tumor Volume, Antineoplastic Agents, Breast Neoplasms, Catalytic Domain, Down-Regulation, Enzyme Inhibitors, Insulin Receptor Substrate Proteins, Scid, Phosphatidylinositol 3-Kinases, Protein Binding, Proto-Oncogene Proteins C-Akt, Erbb-3,
Affiliazioni:
*** IBB - CNR ***
Department of Experimental Oncology, Regina National Elena Cancer Institute, Molecular Oncogenesis Laboratory, Via delle Messi d'Oro 156, 0158 Rome, Italy
Regina Elena National Cancer Institute, SAFU, Via delle Messi d'Oro 156, Rome, Italy
Department of Pathology, Regina Elena Cancer Institute, Via E. Chianesi 54, Rome, Italy
Department of Biological Sciences, CIRPeB, University of Naples 'Federico II' and IBB CNR, Via Giovanni Paladino 39, Naples, Italy
Department of Oncology, Regina Elena Cancer Institute, Via E. Chianesi 54, Rome, Italy
Riferimenti:
Liu, P., Cheng, H., Roberts, T.M., Zhao, J.J., Targeting the phosphoinositide 3-kinase pathway in cancer (2009) Nat Rev Drug Discov, 8, pp. 627-64
Engelman, J.A., Targeting signaling in cancer: Opportunities, challenges and limitation (2009) Nat Rev Cancer, 9, pp. 550-562
Yuan, T.L., Canntley, L.C., PI3K pathway alteration in cancer: Variation on a theme (2008) Oncogene, 27, pp. 5497-5510
Willems, L., Tamburini, J., Chapuis, N., Lacombe, C., Mayeux, P., Bouscary, D., PI3K and mTOR signaling pathways in cancer: New data on targeted therapies (2012) Curr Oncol Rep, 14, pp. 129-138
Lou, J., Manning, B.D., Cantley, L.C., Targeting the PI3K-Akt pathway in human cancer: Rationale and promise (2003) Cancer Cell, 4, pp. 257-262
Arteaga, C.L., Sliwkowski, M.X., Osborne, C.K., Perez, E.A., Puglisi, F., Gianni, L., Treatment of HER2-positive breast cancer: Current status and future prospective (2011) Nat Rev Clin Oncol, 9, pp. 16-32
Di Fiore, P.P., Pierce, J.H., Kraus, M.H., Segatto, O., King, C.R., Aaronson, S.A., ErbB-2 is a potent oncogene when overexpressed in NIH73T3 cells (1987) Science, 237, pp. 178-182
Slamon, D.J., Clark, G.M., Wong, S.G., Levin, W.J., Ullrich, A., McGuire, W.L., Human breast cancer: Correlation of relapse and survival with amplified HER-2/neu oncogene (1987) Science, 235, pp. 177-182
Slamon, D.J., Godolphin, W., Jones, L.A., Holt, J.A., Wong, S.G., Keith, D.E., Studies of HER2/neu proto-oncogene in human breast and ovarian cancer (1989) Science, 244, pp. 707-712
Segatto, O., Lonardo, F., Helin, K., Wexler, D., Fazioli, F., Rhee, S.G., ErbB-2 autophosphorylation is required for mitogenic action and high affinity substrate coupling (1992) Oncogene, 7, pp. 1339-1346
Cho, H.S., Mason, K., Ramyar, K.X., Stanley, A.M., Gabelli, S.B., Denney Jr., D.W., Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab (2003) Nature, 421, pp. 756-760
Molina, M.A., Codony-Servat, J., Albanell, J., Rojo, F., Arribas, J., Baselga, J., Trastuzumab (Herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells (2001) Cancer Res, 61, pp. 4744-4749
Hudis, C.A., Trastuzumab-mechanism of action and use in clinical practice (2007) N Engl J Med, 357, pp. 39-51
Slamon, D.J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpress HER2 (2001) N Engl J Med, 344, pp. 783-792
Marty, M., Cognetti, F., Maraninchi, D., Snyder, R., Mauriac, L., Tubiana-Hulin, M., Randomized phase II Trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with epidermal growth factor-2-positive metastatic breast cancer administrated as first line treatment: The M77001 Study Group (2005) J Clin Oncol, 23, pp. 4265-4274
Oakman, C., Sapino, C., Marchiò, C., Pestrin, M., Biganzoli, L., Di Leo, A., Chemotherapy with and without trastuzumab (2010) Ann Oncol, 21, pp. vii112-vii119
Normanno, N., Bianco, C., De Luca, A., Maiello, M.R., Salomon, D.S., Target-based agents against ErbB receptors and their ligands: A novel approach to cancer treatment (2003) Endocr Relat Cancer, 10, pp. 1-21
Yarden, Y., Sliwkowski, M.X., Untangling the ErbB signaling network (2001) Nat. Rev. Mol Cell Biol, 2, pp. 127-137
Wallasch, C., Weiss, F.U., Nierderfellner, G., Jallal, B., Issing, W., Ullrich, A., Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3 (1995) EMBO J, 14, pp. 4267-4275
Hellyer, N.J., Cheng, K., Koland, J.G., ErbB3 (HER3) interaction with the p85 regolatory subunit of phosphoinositide3-kinase (1988) Biochem J, 333, pp. 757-763
Sergina, N.V., Rausch, M., Wang, D., Blair, J., Hann, B., Shokat, K.M., Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3 (2007) Nature, 445, pp. 347-441
Berns, K., Horlings, H.M., Hennessy, B.T., Madiredjo, M., Hijmans, E.M., Beelen, K., A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer (2007) Cancer Cell, 12, pp. 395-402
Hynes, N.E., Lane, H.A., ERBB receptors and cancer: The complexity of targeted inhibitors (2005) Nat Rev Cancer, 5, pp. 341-354
Holbro, T., Beerli, R.R., Maurer, F., Koziczak, M., Barbas III, C.F., Hynes, N.E., The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB-2 requires ErbB3 to drive breast cancer tumor cell proliferation (2003) Proc Natl Acad Sci USA, 100, pp. 8933-8938
Siegel, P.M., Ryan, E.D., Cardiff, R.D., Muller, W.J., Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: Implications for human breast cancer (1999) EMBO J, 18, pp. 2149-2164
Cook, R.S., Garrett, R.T., Sanchez, V., Stanford, J.C., Young, C., Chakrabarty, A., ErbB3 ablation impairs PI3K/Akt-dependent mammary tumorigenesis (2011) Cancer Res, 71, pp. 3941-3951
Folgiero, V., Avetrani, P., Bon, G., Di Carlo, S.E., Fabi, A., Nisticò, C., Induction of ErbB-3 expression by a6b4 integrin contributes to Tamoxifen resistance in ERb1-negative breast carcinoma (2008) PLoS ONE, 3, pp. e1592
Vivanco, I., Sawyers, C.L., The phosphatydilinositol 3-kinase Akt pathway in human cancer (2002) Nat Rev Cancer, 2, pp. 489-551
Engelman, J.A., Luo, J., Cantley, L.C., The evolution of phosphatidilinositol 3-kinase of growth and metabolism (2006) Nat Rev Cancer, 7, pp. 606-619
Suenaga, A., Takada, N., Hatakeyama, M., Ichikawa, M., Yu, X., Tomii, K., Novel Mechanism of interaction of p85 subunit of phosphatidylinositol 3-kinase and ErbB3 receptor-derived phosphotyrosyl peptides (2005) J Biol Chem, 280, pp. 1321-1326
Songyang, Z., Shoelson, S.E., Chaudhuri, M., Gish, G., Pawson, T., Haser, W.G., SH2 domains recognize specific phosphopeptide sequences (1993) Cell, 72, pp. 767-778
Damiano, V., Garofalo, S., Rosa, R., Bianco, R., Caputo, R., Gelardi, T., A novel toll-like receptor agonist cooperates with trastuzumab in trastuzumab-resistant breast tumors through multiple mechanisms of action (2009) Clin Cancer Res, 15, pp. 6921-6930
Defazio, A., Chiew, Y.E., Sini, R.L., Janes, P.W., Sutherland, R.L., Expression of c-erbB receptors, heregulin and oestrogen receptor in human breast cancer cell lines (2000) Int J Cancer, 87, pp. 487-498
Folgiero, V., Bachelder, R.E., Bon, G., Sacchi, A., Falcioni, R., Mercurio, A.M., The alpha6beta4 integrin can regulate ErbB-3 expression: Implications for alpha6beta4 signaling and function (2007) Cancer Res, 67, pp. 1645-1652
Saal, L.H., Holm, K., Maurer, M., Memeo, L., Su, T., Wang, X., PIK3CA mutations correlate with hormone receptor, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast cancer (2005) Cancer Res, 65, pp. 2554-2559
Huang, X., Gao, L., Wang, S., McManaman, J.L., Thor, A.D., Yang, X., Heterodimerization of the growth factor receptors erbB2, erbB3, and insulin-like growth factor-I receptor in breast cancer cells resistant to Trastuzumab (2010) Cancer Res, 70, pp. 1204-1214
Zhang, S., Huang, W.C., Li, P., Guo, H., Poh, S.B., Brady, S.W., Combating Trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways (2001) Nature Med, 17, pp. 461-470
Zhu, S., Lee, D.A., Li, S., IL-12 and IL-27 sequential gene therapy via intramuscular electroporation delivery for eliminating distal aggressive tumors (2010) J Immunol, 184, pp. 2348-2354
Sanchez, C.G., Ma, C.X., Crowder, R.J., Guintoli, T., Phommaly, C., Gao, F., Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer (2011) Breast Cancer Res, 13, pp. R21
Engelman, J. A., Targeting signaling in cancer: Opportunities, challenges and limitation (2009) Nat Rev Cancer, 9, pp. 550-562
Yuan, T. L., Canntley, L. C., PI3K pathway alteration in cancer: Variation on a theme (2008) Oncogene, 27, pp. 5497-5510
Arteaga, C. L., Sliwkowski, M. X., Osborne, C. K., Perez, E. A., Puglisi, F., Gianni, L., Treatment of HER2-positive breast cancer: Current status and future prospective (2011) Nat Rev Clin Oncol, 9, pp. 16-32
Di Fiore, P. P., Pierce, J. H., Kraus, M. H., Segatto, O., King, C. R., Aaronson, S. A., ErbB-2 is a potent oncogene when overexpressed in NIH73T3 cells (1987) Science, 237, pp. 178-182
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., McGuire, W. L., Human breast cancer: Correlation of relapse and survival with amplified HER-2/neu oncogene (1987) Science, 235, pp. 177-182
Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Studies of HER2/neu proto-oncogene in human breast and ovarian cancer (1989) Science, 244, pp. 707-712
Cho, H. S., Mason, K., Ramyar, K. X., Stanley, A. M., Gabelli, S. B., Denney Jr., D. W., Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab (2003) Nature, 421, pp. 756-760
Molina, M. A., Codony-Servat, J., Albanell, J., Rojo, F., Arribas, J., Baselga, J., Trastuzumab (Herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells (2001) Cancer Res, 61, pp. 4744-4749
Hudis, C. A., Trastuzumab-mechanism of action and use in clinical practice (2007) N Engl J Med, 357, pp. 39-51
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpress HER2 (2001) N Engl J Med, 344, pp. 783-792
Hellyer, N. J., Cheng, K., Koland, J. G., ErbB3 (HER3) interaction with the p85 regolatory subunit of phosphoinositide3-kinase (1988) Biochem J, 333, pp. 757-763
Sergina, N. V., Rausch, M., Wang, D., Blair, J., Hann, B., Shokat, K. M., Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3 (2007) Nature, 445, pp. 347-441
Hynes, N. E., Lane, H. A., ERBB receptors and cancer: The complexity of targeted inhibitors (2005) Nat Rev Cancer, 5, pp. 341-354
Siegel, P. M., Ryan, E. D., Cardiff, R. D., Muller, W. J., Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: Implications for human breast cancer (1999) EMBO J, 18, pp. 2149-2164
Cook, R. S., Garrett, R. T., Sanchez, V., Stanford, J. C., Young, C., Chakrabarty, A., ErbB3 ablation impairs PI3K/Akt-dependent mammary tumorigenesis (2011) Cancer Res, 71, pp. 3941-3951
Engelman, J. A., Luo, J., Cantley, L. C., The evolution of phosphatidilinositol 3-kinase of growth and metabolism (2006) Nat Rev Cancer, 7, pp. 606-619
Saal, L. H., Holm, K., Maurer, M., Memeo, L., Su, T., Wang, X., PIK3CA mutations correlate with hormone receptor, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast cancer (2005) Cancer Res, 65, pp. 2554-2559
Zhu, S., Lee, D. A., Li, S., IL-12 and IL-27 sequential gene therapy via intramuscular electroporation delivery for eliminating distal aggressive tumors (2010) J Immunol, 184, pp. 2348-2354
Sanchez, C. G., Ma, C. X., Crowder, R. J., Guintoli, T., Phommaly, C., Gao, F., Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer (2011) Breast Cancer Res, 13, pp. R21
Cell Death & (ISSN: 2041-4889, 2041-4889electronic), 2012; 3(12): N/D-N/D.
Tipo di articolo: Journal Article, Abstract, Conference,
Impact factor: 6.044, Impact factor a 5 anni: 6.044
Url: http://www.scopus.com/inward/record.url?eid=2-s2.0-84871250346&partnerID=40&md5=bd670025334313e76f1c52cd79ff9401
Parole chiave: Breast Cancer, Cell Signaling, Growth Factors And Receptors, Oncogenes, Tumor Promotion And Progression, Epidermal Growth Factor Receptor 2, Insulin Receptor Substrate 1, Liposome, Mitogen Activated Protein Kinase 1, P 1257, Phosphatidylinositol 3 Kinase, Phosphatidylinositol 3 Kinase Inhibitor, Phosphopeptide 1257, Protein P85, Trastuzumab, Unclassified Drug, Animal Cell, Animal Experiment, Animal Model, Animal Tissue, Antineoplastic Activity, Apoptosis, Article, Cancer Cell Culture, Cell Death, Cell Proliferation, Controlled Study, Drug Efficacy, Electroporation, Enzyme Activity, Enzyme Inhibition, Enzyme Phosphorylation, Female, Gene Overexpression, Human, Human Cell, Human Tissue, In Vitro Study, In Vivo Gene Transfer, Mouse, Nonhuman, Priority Journal, Protein Expression, Protein Function, Protein Protein Interaction, Protein Targeting, Treatment Response, Tumor Growth, Tumor Volume, Antineoplastic Agents, Breast Neoplasms, Catalytic Domain, Down-Regulation, Enzyme Inhibitors, Insulin Receptor Substrate Proteins, Scid, Phosphatidylinositol 3-Kinases, Protein Binding, Proto-Oncogene Proteins C-Akt, Erbb-3,
Affiliazioni:
*** IBB - CNR ***
Department of Experimental Oncology, Regina National Elena Cancer Institute, Molecular Oncogenesis Laboratory, Via delle Messi d'Oro 156, 0158 Rome, Italy
Regina Elena National Cancer Institute, SAFU, Via delle Messi d'Oro 156, Rome, Italy
Department of Pathology, Regina Elena Cancer Institute, Via E. Chianesi 54, Rome, Italy
Department of Biological Sciences, CIRPeB, University of Naples 'Federico II' and IBB CNR, Via Giovanni Paladino 39, Naples, Italy
Department of Oncology, Regina Elena Cancer Institute, Via E. Chianesi 54, Rome, Italy
Riferimenti:
Liu, P., Cheng, H., Roberts, T.M., Zhao, J.J., Targeting the phosphoinositide 3-kinase pathway in cancer (2009) Nat Rev Drug Discov, 8, pp. 627-64
Engelman, J.A., Targeting signaling in cancer: Opportunities, challenges and limitation (2009) Nat Rev Cancer, 9, pp. 550-562
Yuan, T.L., Canntley, L.C., PI3K pathway alteration in cancer: Variation on a theme (2008) Oncogene, 27, pp. 5497-5510
Willems, L., Tamburini, J., Chapuis, N., Lacombe, C., Mayeux, P., Bouscary, D., PI3K and mTOR signaling pathways in cancer: New data on targeted therapies (2012) Curr Oncol Rep, 14, pp. 129-138
Lou, J., Manning, B.D., Cantley, L.C., Targeting the PI3K-Akt pathway in human cancer: Rationale and promise (2003) Cancer Cell, 4, pp. 257-262
Arteaga, C.L., Sliwkowski, M.X., Osborne, C.K., Perez, E.A., Puglisi, F., Gianni, L., Treatment of HER2-positive breast cancer: Current status and future prospective (2011) Nat Rev Clin Oncol, 9, pp. 16-32
Di Fiore, P.P., Pierce, J.H., Kraus, M.H., Segatto, O., King, C.R., Aaronson, S.A., ErbB-2 is a potent oncogene when overexpressed in NIH73T3 cells (1987) Science, 237, pp. 178-182
Slamon, D.J., Clark, G.M., Wong, S.G., Levin, W.J., Ullrich, A., McGuire, W.L., Human breast cancer: Correlation of relapse and survival with amplified HER-2/neu oncogene (1987) Science, 235, pp. 177-182
Slamon, D.J., Godolphin, W., Jones, L.A., Holt, J.A., Wong, S.G., Keith, D.E., Studies of HER2/neu proto-oncogene in human breast and ovarian cancer (1989) Science, 244, pp. 707-712
Segatto, O., Lonardo, F., Helin, K., Wexler, D., Fazioli, F., Rhee, S.G., ErbB-2 autophosphorylation is required for mitogenic action and high affinity substrate coupling (1992) Oncogene, 7, pp. 1339-1346
Cho, H.S., Mason, K., Ramyar, K.X., Stanley, A.M., Gabelli, S.B., Denney Jr., D.W., Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab (2003) Nature, 421, pp. 756-760
Molina, M.A., Codony-Servat, J., Albanell, J., Rojo, F., Arribas, J., Baselga, J., Trastuzumab (Herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells (2001) Cancer Res, 61, pp. 4744-4749
Hudis, C.A., Trastuzumab-mechanism of action and use in clinical practice (2007) N Engl J Med, 357, pp. 39-51
Slamon, D.J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpress HER2 (2001) N Engl J Med, 344, pp. 783-792
Marty, M., Cognetti, F., Maraninchi, D., Snyder, R., Mauriac, L., Tubiana-Hulin, M., Randomized phase II Trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with epidermal growth factor-2-positive metastatic breast cancer administrated as first line treatment: The M77001 Study Group (2005) J Clin Oncol, 23, pp. 4265-4274
Oakman, C., Sapino, C., Marchiò, C., Pestrin, M., Biganzoli, L., Di Leo, A., Chemotherapy with and without trastuzumab (2010) Ann Oncol, 21, pp. vii112-vii119
Normanno, N., Bianco, C., De Luca, A., Maiello, M.R., Salomon, D.S., Target-based agents against ErbB receptors and their ligands: A novel approach to cancer treatment (2003) Endocr Relat Cancer, 10, pp. 1-21
Yarden, Y., Sliwkowski, M.X., Untangling the ErbB signaling network (2001) Nat. Rev. Mol Cell Biol, 2, pp. 127-137
Wallasch, C., Weiss, F.U., Nierderfellner, G., Jallal, B., Issing, W., Ullrich, A., Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3 (1995) EMBO J, 14, pp. 4267-4275
Hellyer, N.J., Cheng, K., Koland, J.G., ErbB3 (HER3) interaction with the p85 regolatory subunit of phosphoinositide3-kinase (1988) Biochem J, 333, pp. 757-763
Sergina, N.V., Rausch, M., Wang, D., Blair, J., Hann, B., Shokat, K.M., Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3 (2007) Nature, 445, pp. 347-441
Berns, K., Horlings, H.M., Hennessy, B.T., Madiredjo, M., Hijmans, E.M., Beelen, K., A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer (2007) Cancer Cell, 12, pp. 395-402
Hynes, N.E., Lane, H.A., ERBB receptors and cancer: The complexity of targeted inhibitors (2005) Nat Rev Cancer, 5, pp. 341-354
Holbro, T., Beerli, R.R., Maurer, F., Koziczak, M., Barbas III, C.F., Hynes, N.E., The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB-2 requires ErbB3 to drive breast cancer tumor cell proliferation (2003) Proc Natl Acad Sci USA, 100, pp. 8933-8938
Siegel, P.M., Ryan, E.D., Cardiff, R.D., Muller, W.J., Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: Implications for human breast cancer (1999) EMBO J, 18, pp. 2149-2164
Cook, R.S., Garrett, R.T., Sanchez, V., Stanford, J.C., Young, C., Chakrabarty, A., ErbB3 ablation impairs PI3K/Akt-dependent mammary tumorigenesis (2011) Cancer Res, 71, pp. 3941-3951
Folgiero, V., Avetrani, P., Bon, G., Di Carlo, S.E., Fabi, A., Nisticò, C., Induction of ErbB-3 expression by a6b4 integrin contributes to Tamoxifen resistance in ERb1-negative breast carcinoma (2008) PLoS ONE, 3, pp. e1592
Vivanco, I., Sawyers, C.L., The phosphatydilinositol 3-kinase Akt pathway in human cancer (2002) Nat Rev Cancer, 2, pp. 489-551
Engelman, J.A., Luo, J., Cantley, L.C., The evolution of phosphatidilinositol 3-kinase of growth and metabolism (2006) Nat Rev Cancer, 7, pp. 606-619
Suenaga, A., Takada, N., Hatakeyama, M., Ichikawa, M., Yu, X., Tomii, K., Novel Mechanism of interaction of p85 subunit of phosphatidylinositol 3-kinase and ErbB3 receptor-derived phosphotyrosyl peptides (2005) J Biol Chem, 280, pp. 1321-1326
Songyang, Z., Shoelson, S.E., Chaudhuri, M., Gish, G., Pawson, T., Haser, W.G., SH2 domains recognize specific phosphopeptide sequences (1993) Cell, 72, pp. 767-778
Damiano, V., Garofalo, S., Rosa, R., Bianco, R., Caputo, R., Gelardi, T., A novel toll-like receptor agonist cooperates with trastuzumab in trastuzumab-resistant breast tumors through multiple mechanisms of action (2009) Clin Cancer Res, 15, pp. 6921-6930
Defazio, A., Chiew, Y.E., Sini, R.L., Janes, P.W., Sutherland, R.L., Expression of c-erbB receptors, heregulin and oestrogen receptor in human breast cancer cell lines (2000) Int J Cancer, 87, pp. 487-498
Folgiero, V., Bachelder, R.E., Bon, G., Sacchi, A., Falcioni, R., Mercurio, A.M., The alpha6beta4 integrin can regulate ErbB-3 expression: Implications for alpha6beta4 signaling and function (2007) Cancer Res, 67, pp. 1645-1652
Saal, L.H., Holm, K., Maurer, M., Memeo, L., Su, T., Wang, X., PIK3CA mutations correlate with hormone receptor, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast cancer (2005) Cancer Res, 65, pp. 2554-2559
Huang, X., Gao, L., Wang, S., McManaman, J.L., Thor, A.D., Yang, X., Heterodimerization of the growth factor receptors erbB2, erbB3, and insulin-like growth factor-I receptor in breast cancer cells resistant to Trastuzumab (2010) Cancer Res, 70, pp. 1204-1214
Zhang, S., Huang, W.C., Li, P., Guo, H., Poh, S.B., Brady, S.W., Combating Trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways (2001) Nature Med, 17, pp. 461-470
Zhu, S., Lee, D.A., Li, S., IL-12 and IL-27 sequential gene therapy via intramuscular electroporation delivery for eliminating distal aggressive tumors (2010) J Immunol, 184, pp. 2348-2354
Sanchez, C.G., Ma, C.X., Crowder, R.J., Guintoli, T., Phommaly, C., Gao, F., Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer (2011) Breast Cancer Res, 13, pp. R21
Engelman, J. A., Targeting signaling in cancer: Opportunities, challenges and limitation (2009) Nat Rev Cancer, 9, pp. 550-562
Yuan, T. L., Canntley, L. C., PI3K pathway alteration in cancer: Variation on a theme (2008) Oncogene, 27, pp. 5497-5510
Arteaga, C. L., Sliwkowski, M. X., Osborne, C. K., Perez, E. A., Puglisi, F., Gianni, L., Treatment of HER2-positive breast cancer: Current status and future prospective (2011) Nat Rev Clin Oncol, 9, pp. 16-32
Di Fiore, P. P., Pierce, J. H., Kraus, M. H., Segatto, O., King, C. R., Aaronson, S. A., ErbB-2 is a potent oncogene when overexpressed in NIH73T3 cells (1987) Science, 237, pp. 178-182
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., McGuire, W. L., Human breast cancer: Correlation of relapse and survival with amplified HER-2/neu oncogene (1987) Science, 235, pp. 177-182
Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Studies of HER2/neu proto-oncogene in human breast and ovarian cancer (1989) Science, 244, pp. 707-712
Cho, H. S., Mason, K., Ramyar, K. X., Stanley, A. M., Gabelli, S. B., Denney Jr., D. W., Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab (2003) Nature, 421, pp. 756-760
Molina, M. A., Codony-Servat, J., Albanell, J., Rojo, F., Arribas, J., Baselga, J., Trastuzumab (Herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells (2001) Cancer Res, 61, pp. 4744-4749
Hudis, C. A., Trastuzumab-mechanism of action and use in clinical practice (2007) N Engl J Med, 357, pp. 39-51
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpress HER2 (2001) N Engl J Med, 344, pp. 783-792
Hellyer, N. J., Cheng, K., Koland, J. G., ErbB3 (HER3) interaction with the p85 regolatory subunit of phosphoinositide3-kinase (1988) Biochem J, 333, pp. 757-763
Sergina, N. V., Rausch, M., Wang, D., Blair, J., Hann, B., Shokat, K. M., Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3 (2007) Nature, 445, pp. 347-441
Hynes, N. E., Lane, H. A., ERBB receptors and cancer: The complexity of targeted inhibitors (2005) Nat Rev Cancer, 5, pp. 341-354
Siegel, P. M., Ryan, E. D., Cardiff, R. D., Muller, W. J., Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: Implications for human breast cancer (1999) EMBO J, 18, pp. 2149-2164
Cook, R. S., Garrett, R. T., Sanchez, V., Stanford, J. C., Young, C., Chakrabarty, A., ErbB3 ablation impairs PI3K/Akt-dependent mammary tumorigenesis (2011) Cancer Res, 71, pp. 3941-3951
Engelman, J. A., Luo, J., Cantley, L. C., The evolution of phosphatidilinositol 3-kinase of growth and metabolism (2006) Nat Rev Cancer, 7, pp. 606-619
Saal, L. H., Holm, K., Maurer, M., Memeo, L., Su, T., Wang, X., PIK3CA mutations correlate with hormone receptor, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast cancer (2005) Cancer Res, 65, pp. 2554-2559
Zhu, S., Lee, D. A., Li, S., IL-12 and IL-27 sequential gene therapy via intramuscular electroporation delivery for eliminating distal aggressive tumors (2010) J Immunol, 184, pp. 2348-2354
Sanchez, C. G., Ma, C. X., Crowder, R. J., Guintoli, T., Phommaly, C., Gao, F., Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer (2011) Breast Cancer Res, 13, pp. R21
The phosphoinositide 3-kinases (PI3Ks) are heterodimers consisting of the catalytic subunit p110 and the regulatory subunit p85. The PI3K/Akt pathway is strongly deregulated in breast cancer (BC) representing one of the mechanisms of resistance to therapies. Therefore, the identification of inhibitors of PI3K components represents one of the main goals to produce therapeutic agents. Here, we evaluated the efficacy of a phosphopeptide 1257 (P-1257) that targeting p85 strongly inhibits PI3K activity. We tested the effects of P-1257 administration in vitro and in vivo using BC cells expressing different levels of ErbB-2 and resistant or responsive to Trastuzumab. We demonstrated that inhibition of p85 activity by P-1257 induces cell death and sensitizes JIMT-1 and KPL-4 ErbB-2-overexpressing BC cells to Trastuzumab treatment. It is noteworthy that P-1257 delivery in vivo by electroporation or liposomes significantly inhibits the proliferation of tumor cells engrafted at subcutaneous and visceral sites. Overall, our data indicate that the p85 subunit is a valid target for therapeutic approaches and suggest that the structure of the peptide used in our study could be utilized for the development of novel drugs to apply in combination with therapies that fail to cure BCs with high PI3K activity. © 2012 Macmillan Publishers Limited All rights reserved.
Nessun risultato. |
| 99mTc-MIBI in the Evaluation of 7 Breast Cancer Biology (dominio pubblico) (140 visite) |
| Aptamer-mediated impairment of EGFR-integrin αvβ3 complex inhibits vasculogenic mimicry and growth of triple-negative breast cancers (dominio pubblico) (170 visite) |
| Inhibition of Bone Marrow-Derived Mesenchymal Stem Cells Homing Towards Triple-Negative Breast Cancer Microenvironment Using an Anti-PDGFRβ Aptamer. (dominio pubblico) (164 visite) |
| Recent Advances in Nuclear Imaging of Receptor Expression to Guide Targeted Therapies in Breast Cancer (dominio pubblico) (51 visite) |
| Recruitment of stromal cells into tumour microenvironment promote the metastatic spread of breast cancer (accesso riservato) (2 visite) |
| Targeted imaging and inhibition of triple-negative breast cancer metastases by a PDGFRβ aptamer (dominio pubblico) (96 visite) |
| Therapeutic Potential of a Novel αvβ3 Antagonist to Hamper the Aggressiveness of Mesenchymal Triple Negative Breast Cancer Sub-Type (dominio pubblico) (62 visite) |
Vai a fine pagina Versione per copia e incolla facile Esporta tutto in BibTeX Esporta tutto in EndNote
Hill BS, Sarnella A, D'Avino G, Zannetti A
* Recruitment of stromal cells into tumour microenvironment promote the metastatic spread of breast cancer (86 visite) (PDF 2 visite)
Semin Cancer Biol (ISSN: 1044-579xlinking), 2020 Feb; 60: 202-213.
Impact Factor: 11.09
Dettagli Esporta in BibTeX Esporta in EndNote
Salvatore B, Caprio MG, Hill BS, Sarnella A, Roviello GN, Zannetti A
* Recent Advances in Nuclear Imaging of Receptor Expression to Guide Targeted Therapies in Breast Cancer (104 visite) (PDF 51 visite)
Cancers (ISSN: 2072-6694linking), 2019 Oct 22; 11(10): N/D-N/D.
Impact Factor: 6.162
Dettagli Esporta in BibTeX Esporta in EndNote
Esposito MV, Minopoli G, Esposito L, D'Argenio V, Di Maggio F, Sasso E, D'Aiuto M, Zambrano N, Salvatore F
* A Functional Analysis of the Unclassified Pro2767Ser BRCA2 Variant Reveals Its Potential Pathogenicity that Acts by Hampering DNA Binding and Homology-Mediated DNA Repair (50 visite)
Cancers (ISSN: 2072-6694linking), 2019 Sep 28; 11(10): N/D-N/D.
Impact Factor: 6.102
Dettagli Esporta in BibTeX Esporta in EndNote
Fellin F, Iacco M, D'Avino V, Tommasino F, Farace P, Palma G, Conson M, Giacomelli I, Zucchetti C, Falcinelli L, Amichetti M, Aristei C, Cella L
* Potential skin morbidity reduction with intensity-modulated proton therapy for breast cancer with nodal involvement (42 visite)
Acta Oncol (ISSN: 0284-186xlinking), 2019 Jun; 58 (6 ): 934-942.
Impact Factor: 2.997
Dettagli Esporta in BibTeX Esporta in EndNote
Hill BS, Sarnella A, Capasso D, Comegna D, Del Gatto A, Gramanzini M, Albanese S, Saviano M, Zaccaro L, Zannetti A
* Therapeutic Potential of a Novel alphavbeta(3) Antagonist to Hamper the Aggressiveness of Mesenchymal Triple Negative Breast Cancer Sub-Type (162 visite) (PDF 62 visite)
Cancers (ISSN: 2072-6694linking), 2019 Jan 24; 11(2): 139-139.
Impact Factor: 6.126
Dettagli Esporta in BibTeX Esporta in EndNote
Camorani S, Hill B, Collina F, Gargiulo S, Napolitano M, Cantile M, Di Bonito M, Botti G, Fedele M, Zannetti A, Cerchia L
* Targeted imaging and inhibition of triple-negative breast cancer metastases by a PDGFRβ aptamer (423 visite) (PDF 96 visite)
Theranostics (ISSN: 1838-7640, 1838-7640electronic, 1838-7640linking), 2018 Oct 6; 8(18): 5178-5199.
Impact Factor: 8.537
Dettagli Esporta in BibTeX Esporta in EndNote
Carafa V, Nebbioso A, Cuomo F, Rotili D, Cobellis G, Bontempo P, Baldi A, Spugnini EP, Citro G, Chambery A, Russo R, Ruvo M, Ciana P, Maravigna L, Shaik J, Radaelli E, De Antonellis P, Tarantino D, Pirolli A, Ragno R, Zollo M, Stunnenberg HG, Mai A, Altucci L
* RIP1-HAT1-SIRT Complex Identification and Targeting in Treatment and Prevention of Cancer (98 visite)
Clin Cancer Res (ISSN: 1078-0432print, 1078-0432linking), 2018 Jun 15; 24(12): 2886-2900.
Impact Factor: 6.488
Dettagli Esporta in BibTeX Esporta in EndNote
Di Gregorio E, Ferrauto G, Lanzardo S, Gianolio E, Aime S
* Early diagnosis of breast cancer by using Fast field cycling relaxometry (FFC-NMRD): investigations of ex-vivo murine breast tissue (118 visite)
Breast Cancer Radiology, 2018; N/D: N/D-N/D.
Impact Factor: 1.712
Dettagli Esporta in BibTeX Esporta in EndNote
Fusella F, Secli L, Busso E, Krepelova A, Moiso E, Rocca S, Conti L, Annaratone L, Rubinetto C, Mello-grand M, Singh V, Chiorino G, Silengo L, Altruda F, Turco E, Morotti A, Oliviero S, Castellano I, Cavallo F, Provero P, Tarone G, Brancaccio M
* The IKK/NF-kappaB signaling pathway requires Morgana to drive breast cancer metastasis (103 visite)
Nat Commun (ISSN: 2041-1723, 2041-1723electronic), 2017 Nov 21; 8(1): 1636-1636.
Impact Factor: 12.353
Dettagli Esporta in BibTeX Esporta in EndNote
Camorani S, Hill BS, Fontanella R, Greco A, Gramanzini M, Auletta L, Gargiulo S, Albanese S, Lucarelli E, Cerchia L, Zannetti A
* Inhibition of Bone Marrow-Derived Mesenchymal Stem Cells Homing Towards Triple-Negative Breast Cancer Microenvironment Using an Anti-PDGFRbeta Aptamer (535 visite) (PDF 164 visite)
Theranostics (ISSN: 1838-7640, 1838-7640electronic), 2017 Aug 22; 7(14): 3595-3607.
Impact Factor: 8.537
Dettagli Esporta in BibTeX Esporta in EndNote
Romeo V, Cuocolo R, Liuzzi R, Riccardi A, Accurso A, Acquaviva A, Buonocore R, Imbriaco M
* Preliminary Results of a Simplified Breast MRI Protocol to Characterize Breast Lesions: Comparison with a Full Diagnostic Protocol and a Review of the Current Literature (154 visite)
Acad Radiol (ISSN: 1076-6332, 1878-4046electronic), 2017 Jun 01; N/D: N/D-N/D.
Impact Factor: 2.11
Dettagli Esporta in BibTeX Esporta in EndNote
Camorani S, Crescenzi E, Gramanzini M, Fedele M, Zannetti A, Cerchia L
* Aptamer-mediated impairment of EGFR-integrin alphavbeta3 complex inhibits vasculogenic mimicry and growth of triple-negative breast cancers (282 visite) (PDF 170 visite)
Sci Rep (ISSN: 2045-2322, 2045-2322electronic, 2045-2322linking), 2017 Apr 20; 7: 46659-46659.
Impact Factor: 4.122
Dettagli Esporta in BibTeX Esporta in EndNote
Longo DL, Moustaghfir FZ, Zerbo A, Consolino L, Anemone A, Bracesco M, Aime S
* EXCI-CEST: Exploiting pharmaceutical excipients as MRI-CEST contrast agents for tumor imaging (170 visite)
Int J Pharm (ISSN: 0378-5173, 1873-3476), 2017; 525(1): 275-281.
Impact Factor: 3.862
Dettagli Esporta in BibTeX Esporta in EndNote
Soprano M, Sorriento D, Rusciano MR, Maione AS, Limite G, Forestieri P, D'Angelo D, D'Alessio M, Campiglia P, Formisano P, Iaccarino G, Bianco R, Illario M
* Oxidative Stress Mediates the Antiproliferative Effects of Nelfinavir in Breast Cancer Cells (139 visite)
Plosone (ISSN: 1932-6203, 1932-6203electronic), 2016 Jun 9; 11(6): e0155970-e0155970.
Impact Factor: 2.806
Dettagli Esporta in BibTeX Esporta in EndNote
Pastore F, Conson M, D'Avino V, Palma G, Liuzzi R, Solla R, Farella A, Salvatore M, Cella L, Pacelli R
* Dose-surface analysis for prediction of severe acute radio-induced skin toxicity in breast cancer patients (261 visite)
Acta Oncol (ISSN: 0284-186x), 2016; 55(4): 466-473.
Impact Factor: 3.156
Dettagli Esporta in BibTeX Esporta in EndNote
Consolino L, Longo DL, Dastrù W, Cutrin JC, Dettori D, Lanzardo S, Oliviero S, Cavallo F, Aime S
* Functional imaging of the angiogenic switch in a transgenic mouse model of human breast cancer by dynamic contrast enhanced magnetic resonance imaging (193 visite)
Int J Cancer (ISSN: 0020-7136), 2016; N/D: N/D-N/D.
Impact Factor: 6.513
Dettagli Esporta in BibTeX Esporta in EndNote
Calce E, Monfregola L, Saviano M, De Luca S
* HER2-mediated anticancer drug delivery: strategies to prepare targeting ligands highly specific for the receptor (398 visite)
Curr Med Chem (ISSN: 0929-8673, 1875-533x, 1875-533xelectronic), 2015 May 20; 22(21): 2525-2538.
Impact Factor: 3.455
Dettagli Esporta in BibTeX Esporta in EndNote
Rizzitelli S, Giustetto P, Cutrin JC, Delli Castelli D, Boffa C, Ruzza M, Menchise V, Molinari F, Aime S, Terreno E
* Sonosensitive theranostic liposomes for preclinical in vivo MRI-guided visualization of doxorubicin release stimulated by pulsed low intensity non-focused ultrasound (315 visite)
J Control Release (ISSN: 0168-3659), 2015 Jan 24; 202: 21-30.
Impact Factor: 7.441
Dettagli Esporta in BibTeX Esporta in EndNote
Longo DL, Dastrù W, Consolino L, Espak M, Arigoni M, Cavallo F, Aime S
* Cluster analysis of quantitative parametric maps from DCE-MRI: Application in evaluating heterogeneity of tumor response to antiangiogenic treatment (345 visite)
Magn Reson Imaging (ISSN: 0730-725x), 2015; 33(6): 725-736.
Impact Factor: 1.98
Dettagli Esporta in BibTeX Esporta in EndNote
Gallicchio R, Giacomobono S, Nardelli A, Pellegrino T, Simeon V, Gattozzi D, Maddalena F, Mainenti PP, Storto G
* Palliative Treatment Of Bone Metastases With Samarium-153 Edtmp At Onset Of Pain (270 visite)
J Bone Miner Metab (ISSN: 0914-8779), 2014 Jul; 32(4): 434-440.
Impact Factor: 2.46
Dettagli Esporta in BibTeX Esporta in EndNote
Calce E, Sandomenico A, Saviano M, Ruvo M, De Luca S
* Cysteine Co-Oxidation Process Driven By Native Peptide Folding: An Example On Her2 Receptor Model System (228 visite)
Amino Acids (ISSN: 0939-4451, 1438-2199, 1438-2199electronic), 2014; 46(5): 1197-1206.
Impact Factor: 3.293
Dettagli Esporta in BibTeX Esporta in EndNote
Formisano L, Nappi L, Rosa R, Marciano R, D'Amato C, D'Amato V, Damiano V, Raimondo L, Iommelli F, Scorziello A, Troncone G, Veneziani BM, Parsons SJ, De Placido S, Bianco R
* Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models (242 visite)
Breast Cancer Res Biomed Central Ltd (ISSN: 1465-5411), 2014; 16(3): R45-R45.
Impact Factor: 0.635
Dettagli Esporta in BibTeX Esporta in EndNote
Pastore F, Faiella A, Solla R, Farella A, Cella L, Liuzzi R, Salzano G, Conson M, Salvatore M, Pacelli R
* Psoriasis In Breast Cancer: Incidence And Impact On Radioinduced Skin Toxicity (196 visite)
Radiother Oncol (ISSN: 0167-8140, 1879-0887), 2014; 111: 486-486.
Impact Factor: 4.363
Dettagli Esporta in BibTeX Esporta in EndNote
Marotta V, Ramundo V, Camera L, Del Prete M, Fonti R, Esposito R, Palmieri G, Salvatore M, Vitale M, Colao A, Faggiano A
* Sorafenib in advanced iodine-refractory differentiated thyroid cancer: Efficacy, safety and exploratory analysis of role of serum thyroglobulin and FDG-PET (284 visite)
Clin Endocrinol (ISSN: 0300-0664, 1365-2265, 1365-2265electronic), 2013 May; 78(5): 760-767.
Impact Factor: 3.353
Dettagli Esporta in BibTeX Esporta in EndNote
Pacelli R, Conson M, Cella L, Liuzzi R, Troncone G, Iorio V, Solla R, Farella A, Scala S, Pagliarulo C, Salvatore M
* Radiation therapy following surgery for localized breast cancer: Outcome prediction by classical prognostic factors and approximated genetic subtypes (221 visite)
J Rad Res Journal Of Radiation Research (ISSN: 1349-9157, 0449-3060, 1349-9157electronic), 2013 Mar 1; 54(2): 292-298.
Impact Factor: 1.691
Dettagli Esporta in BibTeX Esporta in EndNote
Calce E, Monfregola L, Sandomenico A, Saviano M, De Luca S
* Fluorescence study for selecting specific ligands toward HER2 receptor: An example of receptor fragment approach (278 visite)
Eur J Med Chem (ISSN: 0223-5234, 1768-3254, 1768-3254electronic), 2013 Mar; 61: 116-121.
Impact Factor: 3.432
Dettagli Esporta in BibTeX Esporta in EndNote
Cella L, Conson M, Pressello MC, Molinelli S, Schneider U, Donato V, Orecchia R, Salvatore M, Pacelli R
* Hodgkin's lymphoma emerging radiation treatment techniques: Trade-offs between late radio-induced toxicities and secondary malignant neoplasms (243 visite)
Radiat Oncol Radiation Oncology (ISSN: 1748-717x), 2013 Jan 30; 8(1): 22-22.
Impact Factor: 2.36
Dettagli Esporta in BibTeX Esporta in EndNote
Conson M, Faiella A, Iorio V, Cella L, Liuzzi R, Solla R, Romanelli P, Farella A, Salvatore M, Pacelli R
* Her-2 Subtype And Age Affect Local Control In Breast Cancer (234 visite)
Radiother Oncol (ISSN: 0167-8140, 1879-0887, 1879-0887electronic), 2013; 106: N/D-N/D.
Impact Factor: 4.857
Dettagli Esporta in BibTeX Esporta in EndNote
Cella L, Liuzzi R, Conson M, D'Avino V, Salvatore M, Pacelli R
* Development of multivariate NTCP models for radiation-induced hypothyroidism: A comparative analysis (281 visite) (PDF 179 visite)
Radiat Oncol Radiation Oncology (ISSN: 1748-717x), 2012 Dec 27; 7(1): 224-224.
Impact Factor: 2.107
Dettagli Esporta in BibTeX Esporta in EndNote
Campanile F, Maurea S, Mainenti PP, Corvino A, Imbriaco M
* Duodenal Involvement by Breast Cancer (147 visite)
Breast Journal (ISSN: 1075-122x), 2012 Nov; 18(6): 615-616.
Impact Factor: 1.831
Dettagli Esporta in BibTeX Esporta in EndNote
Poletto M, Di Loreto C, Marasco D, Poletto E, Puglisi F, Damante G, Tell G
* Acetylation on critical lysine residues of Apurinic/apyrimidinic endonuclease 1 (APE1) in triple negative breast cancers (256 visite)
Biochemical And Biophysical Research Communications (ISSN: 0006-291x), 2012 Jul 20; 424(1): 34-39.
Impact Factor: 2.406
Dettagli Esporta in BibTeX Esporta in EndNote
Avitabile C, Moggio L, Malgieri G, Capasso D, Di Gaetano S, Saviano M, Pedone C, Romanelli A
* Gamma Sulphate Pna (pna S): Highly Selective Dna Binding Molecule Showing Promising Antigene Activity (260 visite)
Plosone (ISSN: 1932-6203, 1932-6203electronic), 2012 May 7; 7(5): e35774-e35774.
Impact Factor: 3.73
Dettagli Esporta in BibTeX Esporta in EndNote
Pacelli R, Conson M, Cella L, Liuzzi R, Solla R, Iorio V, Farella A, Salvatore M
* Prediction Of Relapse And Contralateral Tumor Using Breast Cancer Clinical Variables And Histochemical Subtypes (185 visite)
Radiother Oncol (ISSN: 0167-8140, 1879-0887, 1879-0887electronic), 2012; 103: s246-s246.
Impact Factor: 4.52
Dettagli Esporta in BibTeX Esporta in EndNote
Troise F, Monti M, Merlino A, Cozzolino F, Fedele C, Russo Krauss I, Sica F, Pucci P, D'Alessio G, De Lorenzo C
* A novel ErbB2 epitope targeted by human antitumor immunoagents (234 visite)
Febs Journal (ISSN: 1742-464x), 2011 Apr; 278(7): 1156-1166.
Impact Factor: 3.79
Dettagli Esporta in BibTeX Esporta in EndNote
Accardo A, Morisco A, Tesauro D, Pedone C, Morelli G
* Naposomes: A new class of peptide-derivatized, target-selective multimodal nanoparticles for imaging and therapeutic applications (297 visite)
Ther Deliv (ISSN: 2041-5990), 2011 Feb; 2(2): 235-257.
Impact Factor: 0
Dettagli Esporta in BibTeX Esporta in EndNote
Gallucci G, Coccaro M, Storto G, Lapadula L, Tartarone A, Nappi A, Cammarota A, Buonerba C, Di Lorenzo G, Fusco V, Aieta M
* The clinical impact of a cardiologic follow-up in breast cancer survivors: an observational study (183 visite)
Int J Immunopathol Pharmacol (ISSN: 0394-6320), 2010 Oct; 23(4): 1221-1227.
Impact Factor: 2.685
Dettagli Esporta in BibTeX Esporta in EndNote
Bombardieri E, Ambrosini V, Aktolun C, Baum RP, Bishof-delaloye A, Del Vecchio S, Maffioli L, Mortelmans L, Oyen W, Pepe G, Chiti A
* In-111-pentetreotide scintigraphy: procedure guidelines for tumour imaging (293 visite)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2010 Jul; 37(7): 1441-1448.
Impact Factor: 5.036
Dettagli Esporta in BibTeX Esporta in EndNote
Del Vecchio S, Zannetti A, Fonti R, Iommelli F, Pizzuti LM, Lettieri A, Salvatore M
* PET/CT in cancer research: From preclinical to clinical applications (436 visite)
Contrast Media Mol Imaging (ISSN: 1555-4309, 1555-4309linking), 2010 Jul; 5(4): 190-200.
Impact Factor: 4.02
Dettagli Esporta in BibTeX Esporta in EndNote
Conson M, D'Amato G, Nieddu V, Pagliarulo C, Iorio V, Vernieri C, Farella A, Solla R, Cella L, Liuzzi R, Punzo G, Salvatore M, Pacelli R
* Patterns of distant and local relapses in breast cancer patients and triple negative subgroup (192 visite)
Meetingproceedings Of The American Association For Cancer Research Annual (ISSN: 0197-016x), 2010 Apr; 51: N/D-N/D.
Impact Factor: 0
Dettagli Esporta in BibTeX Esporta in EndNote
Alberobello AT, D'Esposito V, Marasco D, Doti N, Ruvo M, Bianco R, Tortora G, Esposito I, Fiory F, Miele C, Beguinot F, Formisano P
* Selective Disruption of Insulin-like Growth Factor-1 (IGF-1) Signaling via Phosphoinositide-dependent Kinase-1 Prevents the Protective Effect of IGF-1 on Human Cancer Cell Death (269 visite)
Jbc Papers (ISSN: 0021-9258, 1083-351x, 0021-9258linking), 2010 Feb 26; 285(9): 6563-6572.
Impact Factor: 5.328
Dettagli Esporta in BibTeX Esporta in EndNote
Farina AR, Tacconelli A, Cappabianca L, Cea G, Chioda A, Romanelli A, Pensato S, Pedone C, Gulino A, Mackay AR
* The neuroblastoma tumour-suppressor TrkAI and its oncogenic alternative TrkAIII splice variant exhibit geldanamycin-sensitive interactions with Hsp90 in human neuroblastoma cells (206 visite)
Oncogene (ISSN: 1476-5594, 0950-9232), 2009 Nov 19; 28(46): 4075-4094.
Impact Factor: 7.135
Dettagli Esporta in BibTeX Esporta in EndNote
Imbriaco M, Pisani A, Spinelli L, Cuocolo A, Messalli G, Capuano E, Marmo M, Liuzzi R, Visciano B, Cianciaruso B, Salvatore M
* Effects of enzyme-replacement therapy in patients with Anderson-Fabry disease: a prospective long-term cardiac magnetic resonance imaging study (216 visite)
Heart (ISSN: 1355-6037, 1468-201x), 2009 Jul; 95(13): 1103-1107.
Impact Factor: 5.385
Dettagli Esporta in BibTeX Esporta in EndNote
Illario M, Monaco S, Cavallo AL, Esposito I, Formisano P, D'Andrea LD, Cipolletta E, Trimarco B, Fenzi G, Rossi G, Vitale M
* Calcium-calmodulin-dependent kinase II (CaMKII) mediates insulin-stimulated proliferation and glucose uptake (253 visite)
Cell Signal (ISSN: 0898-6568), 2009 May; 21(5): 786-792.
Impact Factor: 4.094
Dettagli Esporta in BibTeX Esporta in EndNote
Storto G, Nicolai E, Salvatore M
* [18F]FDG-PET-CT for early monitoring of tumor response: When and why (263 visite)
Q J Nucl Med Mol Im (ISSN: 1824-4785, 1824-4478, 1824-4785linking), 2009 Apr; 53(2): 167-180.
Impact Factor: 1.724
Dettagli Esporta in BibTeX Esporta in EndNote
Zaccaro L, Del Gatto A, Pedone C, Saviano M
* Peptides for tumour therapy and diagnosis: current status and future directions (367 visite)
Curr Med Chem (ISSN: 0929-8673, 1875-533x, 1875-533xelectronic), 2009 Mar; 16(7): 780-795.
Impact Factor: 4.708
Dettagli Esporta in BibTeX Esporta in EndNote
Insabato L, Amelio I, Quarto M, Zannetti A, Tolino F, De Mauro G, Cerchia L, Riccio P, Baumhoer D, Condorelli G, Terracciano L, De Franciscis V
* Elevated Expression of the Tyrosine Phosphatase SHP-1 Defines a Subset of High-Grade Breast Tumors (278 visite)
Oncology (ISSN: 0030-2414), 2009; 77(6): 378-384.
Impact Factor: 2.112
Dettagli Esporta in BibTeX Esporta in EndNote
Woo LWL, Fischer DS, Sharland CM, Trusselle M, Foster PA, Chander SK, Di Fiore A, Supuran CT, De Simone G, Purohit A, Reed MJ, Potter BVL
* Anticancer steroid sulfatase inhibitors: synthesis of a potent fluorinated second-generation agent, in vitro and in vivo activities, molecular modeling, and protein crystallography (378 visite)
Mol Cancer Ther (ISSN: 1535-7163, 1538-8514electronic), 2008 Sep; 7(8): 2435-2444.
Impact Factor: 5.003
Dettagli Esporta in BibTeX Esporta in EndNote
Cusanno F, Cisbani E, Colilli S, Fratoni R, Garibaldi F, Giuliani F, Gricia M, Lucentini M, Magliozzi ML, Santarivenere F, Torrioli S, Cinti MN, Pani R, Pellegrini R, Simonetti G, Schillaci O, Del Vecchio S, Salvatore M, Majewski S, De Vincentis G, Scopinaro F
* Results of clinical trials with SPEM (190 visite)
Nucl Instrum Methods Phys Res Sect A, 2007 Feb 1; 497(1): 46-50.
Impact Factor: 3.221
Dettagli Esporta in BibTeX Esporta in EndNote
Garibaldi F, Cisbani E, Colilli S, Cusanno F, Fratoni R, Giuliani F, Gricia M, Lucentini M, Fratoni R, Lo Meo S, Magliozzi ML, Santanvenere F, Cinti MN, Pani R, Pellegrini R, Simonetti G, Schillaci O, Del Vecchio S, Salvatore M, Majewski S, Lanza RC, De Vincentis G, Scopinaro F
* Molecular imaging: High-resolution detectors for early diagnosis and therapy monitoring of breast cancer (231 visite)
Nucl Instrum Meth A (ISSN: 0168-9002), 2006 Dec 20; 569(2SPEC.ISS.): 286-290.
Impact Factor: 1.185
Dettagli Esporta in BibTeX Esporta in EndNote
Del Vecchio S, Zannetti A, Salvatore B, Paone G, Fonti R, Salvatore M
* Functional imaging of multidrug resistance in breast cancer (270 visite)
Phys Med (ISSN: 1120-1797, 1120-1797linking), 2006; 21(SUPPL.1): 24-27.
Impact Factor: 0.313
Dettagli Esporta in BibTeX Esporta in EndNote
Zannetti A, Del Vecchio S, Romanelli A, Scala S, Saviano M, Cali' G, Stoppelli MP, Pedone C, Salvatore M
* Inhibition of Sp1 activity by a decoy PNA-DNA chimera prevents urokinase receptor expression and migration of breast cancer cells (350 visite)
Biochem Pharmacol Biochemical Pharmacology (ISSN: 0006-2952, 1873-2968), 2005 Nov 1; 70(9): 1277-1287.
Impact Factor: 3.617
Dettagli Esporta in BibTeX Esporta in EndNote
Del Vecchio S, Zannetti A, Fonti R, Iommelli F, Sommella I, Potena A, Salvatore M
* 99mTc-MIBI uptake in Bcl-2 overexpressing breast cancer cells during treatment with gefitinib, a selective tyrosine kinase inhibitor (239 visite)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2005 Sep; 32: N/D-N/D.
Impact Factor: 3.883
Dettagli Esporta in BibTeX Esporta in EndNote
Lauria A, Palmiero R, Forni G, Fantacci ME, Imbriaco M, Sodano A, Indovina PL
* A Study On Two Different Cad Systems For Mmammography As An Aid To Radiological Diagnosis In The Search Of Microcalcification Clusters (202 visite)
Eur J Radiol (ISSN: 0720-048x), 2005; 55(2): 264-269.
Impact Factor: 1.888
Dettagli Esporta in BibTeX Esporta in EndNote
Borgatti M, Boyd DD, Lampronti I, Bianchi N, Fabbri E, Saviano M, Romanelli A, Pedone C, Gambari R
* Decoy molecules based on PNA-DNA chimeras and targeting Sp1 transcription factors inhibit the activity of urokinase-type plasminogen activator receptor (uPAR) promoter (248 visite)
Oncology Research (ISSN: 0965-0407), 2005; 15(7-8): 373-383.
Impact Factor: 1.844
Dettagli Esporta in BibTeX Esporta in EndNote
Russo M, Tedesco I, Iacomino G, Palumbo R, Galano G, Russo GL
* Dietary phytochemicals in chemoprevention of cancer (210 visite)
Curr Med Chem (ISSN: 1568-0134), 2005; 5(1): 61-72.
Impact Factor: 3.715
Dettagli Esporta in BibTeX Esporta in EndNote
Zannetti A, Del Vecchio S, Fonti R, Iommelli F, Sommella J, Potena A, Salvatore M
* Gefitinib, A Selective, Tyrosine Kinase Inhibitor Increases 99mtc-Mibi Uptake In Bcl-2 Overexpressing Breast Cancer Cells (248 visite)
Mol Immunol, 2005; 4: 355-355.
Impact Factor: 3.003
Dettagli Esporta in BibTeX Esporta in EndNote
Del Vecchio S, Zannetti A, Fonti R, Iommelli F, Salvatore M
* Tc-99m-MIBI in the evaluation of breast cancer biology (403 visite)
Breast Cancer (ISSN: 9783-540367802), 2004 Jun; 1: 71-81.
Impact Factor: 0.635
Dettagli Esporta in BibTeX Esporta in EndNote
Del Vecchio S, Salvatore M
* Tc-99m-MIBI in the evaluation of breast cancer biology (325 visite) (PDF 140 visite)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2004 Jun; 31(SUPPL.1): S88-S88.
Impact Factor: 3.935
Dettagli Esporta in BibTeX Esporta in EndNote
Aloj L, Zannetti A, Caracó C, Del Vecchio S, Salvatore M
* Bcl-2 overexpression prevents 99mTc-MIBI uptake in breast cancer cell lines (369 visite)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2004; 31(4): 521-527.
Impact Factor: 3.935
Dettagli Esporta in BibTeX Esporta in EndNote
d'Alesio V, Pacelli R, Durante M, Canale Cama G, Cella L, Gialanella G, Grossi G, Pugliese M, Punzo G, Sardi I, Scampoli P, Solla R, Salvatore M
* Lymph nodes in the irradiated field influence the yield of radiation-induced chromosomal aberrations in lymphocytes from breast cancer patients (215 visite)
Int J Radiat Oncol (ISSN: 0360-3016, 1879-355x, 1879-355xelectronic), 2003 Nov 1; 57(3): 732-738.
Impact Factor: 4.285
Dettagli Esporta in BibTeX Esporta in EndNote
Galdiero M, Vitiello M, Galdiero S
* Eukaryotic cell signaling and transcriptional activation induced by bacterial porins (266 visite)
Fems Microbiology Letters (ISSN: 0378-1097), 2003 Sep 12; 226(1): 57-64.
Impact Factor: 1.932
Dettagli Esporta in BibTeX Esporta in EndNote
Del Vecchio S, Zannetti A, Aloj L, Caracò C, Ciarmiello A, Salvatore M
* Inhibition of early Tc-99m-MIBI uptake by Bcl-2 anti-apoptotic protein overexpression in untreated breast carcinoma (351 visite)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2003 Jun; 30(6): 879-887.
Impact Factor: 3.324
Dettagli Esporta in BibTeX Esporta in EndNote
Lomax AJ, Cella L, Weber D, Kurtz JM, Miralbell R
* Potential role of IMRT and protons in the treatment of the breast and regional nodes (204 visite)
Int J Rad Oncol Biol Phys, 2003 Mar 1; 48(3Supplement): 785-792.
Impact Factor: 0.155
Dettagli Esporta in BibTeX Esporta in EndNote
Del Vecchio S, Zannetti A, Aloj L, Salvatore M
* MIBI as prognostic factor in breast cancer (296 visite)
Q J Nucl Med (ISSN: 1124-3937, 1125-0135), 2003 Mar; 47(1): 46-50.
Impact Factor: 2.222
Dettagli Esporta in BibTeX Esporta in EndNote
Lomax AJ, Cella L, Weber D, Kurtz JM, Miralbell R
* Potential role of intensity-modulated photons and protons in the treatment of the breast and regional nodes (191 visite)
Int J Radiat Oncol (ISSN: 0360-3016, 1879-355x, 1879-355xelectronic), 2003; 55(3): 785-792.
Impact Factor: 4.285
Dettagli Esporta in BibTeX Esporta in EndNote
Del Vecchio S, Zannetti A, Ciarmiello A, Aloj L, Caracò C, Fonti R, Botti G, D'Aiuto G, Salvatore M
* Dynamic coupling of Tc-99m-MIBI efflux and apoptotic pathway activation in untreated breast cancer patients (274 visite)
Eur J Nucl Med (ISSN: 1619-7070, 0340-6997, 1619-7089), 2002 Jun; 29(6): 809-814.
Impact Factor: 3.568
Dettagli Esporta in BibTeX Esporta in EndNote
Salvatore M, Fonti R
* New frontiers of nuclear medicine (293 visite)
Tumori (ISSN: 0300-8916, 0300-8916print, 0300-8916linking), 2002 May; 88(3): S60-S60.
Impact Factor: 0.267
Dettagli Esporta in BibTeX Esporta in EndNote
Fonti R, Limite G, Sodano A, Riccardi A, Forestieri P, De Cristofaro G, Pettinato G, Salvatore M
* Sentinel lymph node identification in breast cancer patients (228 visite)
Radiol Med (ISSN: 0033-8362, 1826-6983, 1826-6983electronic), 2002 Apr; 103(4): 370-377.
Impact Factor: 1.368
Dettagli Esporta in BibTeX Esporta in EndNote
Danforth Dn JR, Aloj L, Carrasquillo JA, Bacharach SL, Chow C, Zujewski J, Whatley M, Galen B, Merino M, Neumann RD
* The role of 18F-FDG-PET in the local/regional evaluation of women with breast cancer (191 visite)
Breast Cancer Res Tr Kluwer Academic Publishers (ISSN: 0167-6806), 2002; 75(2): 135-146.
Impact Factor: 3.132
Dettagli Esporta in BibTeX Esporta in EndNote
Del Vecchio S, Zannetti A, Ciarmiello A, Aloj L, Fonti R, Caraco C, Salvatore M
* 99mTc-MIBI uptake and Bcl-2 overexpression in untreated breast cancer patients (238 visite)
Eur J Nucl Med (ISSN: 0340-6997, 1619-7070, 1619-7089), 2001 Sep; 28(8): N/D-N/D.
Impact Factor: 3.464
Dettagli Esporta in BibTeX Esporta in EndNote
Aloj L, Zannetti A, Caraco C, Fonti R, Del Vecchio S, Salvatore M
* 99mTc-MIBI uptake in breast cancer cells during early phases of apoptosis induction with Staurosporine (227 visite)
Eur J Nucl Med (ISSN: 0340-6997, 1619-7070, 1619-7089), 2001 Sep; 28(8): N/D-N/D.
Impact Factor: 3.464
Dettagli Esporta in BibTeX Esporta in EndNote
Aloj L, Del Vecchio S, Zannetti A, Caracò C, Salvatore M
* 99mTc-MIBI uptake is reduced in Bcl-2 overexpressing MCF-7 breast cancer cells (232 visite)
Eur J Nucl Med (ISSN: 0340-6997, 1619-7070, 1619-7089), 2001 Sep; 28(8): N/D-N/D.
Impact Factor: 3.464
Dettagli Esporta in BibTeX Esporta in EndNote
Imbriaco M, Del Vecchio S, Riccardi A, Pace L, Di Salle F, Di Gennaro F, Salvatore M, Sodano A
* Scintimammography with Tc-99m-MIBI versus dynamic MRI for non-invasive characterization of breast masses (260 visite)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2001 Jan; 28(1): 56-63.
Impact Factor: 3.464
Dettagli Esporta in BibTeX Esporta in EndNote
Del Vecchio S, Ciarmiello A, Zannetti A, Fonti R, Botti G, D'Aiuto G, Salvatore M
Efflux rate of Tc-99m-MIBI and apoptosis in untreated breast cancer patients (228 visite)
J Nucl Med (ISSN: 0161-5505, 1535-5667, 1535-5667electronic), 2000 May; 41(5): N/D-N/D.
Impact Factor: 3.617
Dettagli Esporta in BibTeX Esporta in EndNote
Aloj L, Del Vecchio S, Damiano M, Borrelli G, Di Gennaro F, Imbriaco M, Panico L, Bifano D, Pettinato G, Salvatore M
Washout of Tc-99m-MIBI and prognostic factors in untreated breast cancer patients (186 visite)
J Nucl Med (ISSN: 0161-5505, 1535-5667, 1535-5667electronic), 2000 May; 41(5): N/D-N/D.
Impact Factor: 3.617
Dettagli Esporta in BibTeX Esporta in EndNote
Formisano C, Limite G, Lamberti M, Fonti R, Forestieri P
Lymph node mapping and sentinel lymph node biopsy for evaluation of axillary lymph node status in early invasive breast cancer. Our experience (243 visite)
Przegl Lek (ISSN: 0033-2240print, 0033-2240linking), 2000; 57Suppl5: 113-115.
Impact Factor: 0
Dettagli Esporta in BibTeX Esporta in EndNote
Carriero M, Del Vecchio S, Capozzoli M, Franco P, Fontana L, Zannetti A, Botti G, D'Aiuto G, Salvatore M, Stoppelli M
Urokinase receptor interacts with alpha(v)beta(5) vitronectin receptor, promoting urokinase-dependent cell migration in breast cancer (255 visite)
Cancer Res (ISSN: 0008-5472, 1538-7445, 1538-7445electronic), 1999 Oct 15; 59(20): N/D-N/D.
Impact Factor: 8.614
Dettagli Esporta in BibTeX Esporta in EndNote
Aloj L, Del Vecchio S, Damiano M, Zannetti A, Di Gennaro F, Imbriaco M, Salvatore M
Fractional retention of 99mTc-MIBI and proliferation in untreated breast cancer (221 visite)
Eur J Nucl Med (ISSN: 0340-6997, 1619-7070, 1619-7089), 1999 Sep; 26(9): N/D-N/D.
Impact Factor: 3.239
Dettagli Esporta in BibTeX Esporta in EndNote
Salvatore M, Del Vecchio S
Dynamic imaging: Scintimammography (265 visite)
Eur J Radiol Elsevier Sci Ireland Ltd (ISSN: 0720-048x), 1998 May; 27(SUPPL.2): S259-S259.
Impact Factor: 0.537
Dettagli Esporta in BibTeX Esporta in EndNote
Ciarmiello A, Del Vecchio S, Silvestro P, Potena MI, Carriero MV, Thomas R, Botti G, D'Aiuto G, Salvatore M
Tumor clearance of technetium 99m-sestamibi as a predictor of response to neoadjuvant chemotherapy for locally advanced breast cancer (224 visite)
Journal Of Clinical Oncology (ISSN: 0732-183x), 1998 May; 16(5): 1677-1683.
Impact Factor: 8.228
Dettagli Esporta in BibTeX Esporta in EndNote
Mansi L, Rambaldi PF, Cuccurullo V, Pecori B, Quarantelli M, Fallanca F, Del Vecchio E
Diagnostic and prognostic role of 99mTc-Tetrofosmin in breast cancer (167 visite)
Q J Nucl Med (ISSN: 1124-3937, 1125-0135), 1997 Sep; 41(3): 239-250.
Impact Factor: 2.125
Dettagli Esporta in BibTeX Esporta in EndNote
Del Vecchio S, Ciarmiello A, Pace L, Potena MI, Carriero MV, Mainolfi C, Thomas R, D'Aiuto G, Tsuruo T, Salvatore M
Fractional retention of technetium-99m-sestamibi as an index of P- glycoprotein expression in untreated breast cancer patients (235 visite)
J Nucl Med (ISSN: 0161-5505, 1535-5667, 1535-5667electronic), 1997 Sep; 38(9): 1348-1351.
Impact Factor: 3.491
Dettagli Esporta in BibTeX Esporta in EndNote
Cook JA, Krishna MC, Pacelli R, DeGraff W, Liebmann J, Mitchell JB, Russo A, Wink DA
Nitric oxide enhancement of melphalan-induced cytotoxicity (299 visite)
Br J Cancer (ISSN: 0007-0920, 0007-0920print, 0007-0920linking), 1997 Sep; 76(3): 325-334.
Impact Factor: 2.938
Dettagli Esporta in BibTeX Esporta in EndNote
Carriero MV, Del Vecchio S, Franco P, Potena MI, Chiaradonna F, Botti G, Stoppelli MP, Salvatore M
Vitronectin binding to urokinase receptor in human breast cancer (256 visite)
Clin Cancer Res (ISSN: 1078-0432, 1078-0432linking, 1078-0432print), 1997 Sep; 3(8): 1299-1308.
Impact Factor: 3.419
Dettagli Esporta in BibTeX Esporta in EndNote
Lastoria S, Varrella P, Mainolfi C, Piccolo S, Acampa W, Apicella A, Muto P, Thomas R, DAiuto G, Panico R, Salvatore M
Fluorine-18 PET imaging of primary breast cancer: Preliminary results (120 visite)
J Nucl Med (ISSN: 0161-5505, 1535-5667, 1535-5667electronic), 1997 May; 38(5SUPPL.): N/D-N/D.
Impact Factor: 3.491
Dettagli Esporta in BibTeX Esporta in EndNote
Vecchio SD, Ciarmiello A, Potena MI, Carriero MV, Mainolfi C, Botti G, Thomas R, Cerra M, D'Aiuto G, Tsuruo T, Salvatore M
In vivo detection of multidrug-resistant (MDR1) phenotype by technetium-99m sestamibi scan in untreated breast cancer patients (219 visite)
Eur J Nucl Med (ISSN: 0340-6997print, 0340-6997linking), 1997 Feb; 24(2): 150-159.
Impact Factor: 5.036
Dettagli Esporta in BibTeX Esporta in EndNote
Lastoria S, Varrella P, Thomas R, DAiuto G, Acampa W, Vergara E, Piccolo S, Muto P, Salvatore M
Planning and monitoring the treatment in breast cancer by scintimammography with Tc-99m MIBI (185 visite)
J Nucl Med (ISSN: 0161-5505, 1535-5667, 1535-5667electronic), 1996 May; 37(5SUPPL.): N/D-N/D.
Impact Factor: 3.491
Dettagli Esporta in BibTeX Esporta in EndNote
Varrella P, Lastoria S, Vergara E, Acampa W, Maurea S, Salvatore M
Tc-99m MIBI Scintimammography for monitoring tumor response in patients with advanced breast cancer (132 visite)
J Nucl Med (ISSN: 0161-5505, 1535-5667, 1535-5667electronic), 1995; 36(5SUPPL.): N/D-N/D.
Impact Factor: 3.491
Dettagli Esporta in BibTeX Esporta in EndNote
Carriero MV, Franco P, Del Vecchio S, Massa O, Botti G, D'Aiuto G, Stoppelli MP, Salvatore M
Tissue distribution of soluble and receptor-bound urokinase in human breast cancer using a panel of monoclonal antibodies (284 visite)
Cancer Res (ISSN: 0008-5472, 1538-7445, 1538-7445electronic), 1994 Oct 15; 54(20): 5445-5454.
Impact Factor: 8.426
Dettagli Esporta in BibTeX Esporta in EndNote
Del Vecchio S, Stoppelli MP, Carriero MV, Fonti R, Massa O, Li PY, Botti G, Cerra M, D'Aiuto G, Esposito G, Salvatore M
IN-VITRO RECEPTOR IMAGING FOR CHARACTERIZATION OF HUMAN SOLID TUMORS (169 visite)
Nucl Med Biol (ISSN: 0883-2897, 0969-8051), 1994 Jul; 21(5): 771-774.
Impact Factor: 1.042
Dettagli Esporta in BibTeX Esporta in EndNote
Carriero MV, Stoppelli MP, Del Vecchio S, Franco P, Massa O, Fonti R, Salvatore M
Comparative distribution of urokinase receptor and urokinase in human breast cancer (192 visite)
Meetingproceedings Of The American Association For Cancer Research Annual (ISSN: 0197-016x), 1994; 35(0): N/D-N/D.
Impact Factor: 0
Dettagli Esporta in BibTeX Esporta in EndNote
FRITTITTA L, VIGNERI R, PAPA V, GOLDFINE I, GRASSO G, TRISCHITTA V
Structural and functional studies of insulin receptors in human breast cancer (288 visite)
Breast Cancer Res Tr Kluwer Academic Publishers (ISSN: 0167-6806), 1993; 25(1): 73-82.
Impact Factor: 2.43
Dettagli Esporta in BibTeX Esporta in EndNote
Della Ragione F, Oliva A, Palumbo R, Russo GL, Gragnaniello V, Zappia V
Deficiency of 5'-deoxy-5'-methylthioadenosine phosphorylase activity in malignancy. Absence of the protein in human enzyme-deficient cell lines (167 visite)
Biochem J (ISSN: 0264-6021print, 0264-6021linking, 1470-8728electronic), 1992 Jan 15; 281(Pt2): 533-538.
Impact Factor: 3.579
Dettagli Esporta in BibTeX Esporta in EndNote
D'Aiuto G, Del Vecchio S, Mansi L, D'Aprile M, Botti G, Salvatore M
Malignant melanoma of the nipple: A case studied with radiolabeled monoclonal antibody (371 visite)
Tumori (ISSN: 0300-8916, 0300-8916print, 0300-8916linking), 1991 Oct 31; 77(5): 449-451.
Impact Factor: 0.408
Dettagli Esporta in BibTeX Esporta in EndNote
Iaffaioli RV, Frasci G, Tortora G, Ciardiello F, Nuzzo F, Scala S, Pacelli R, Bianco AR
Effect of thymic extract 'thymostimulin' on the incidence of infections and myelotoxicity during adjuvant chemotherapy for breast cancer (345 visite)
Thymus (ISSN: 0165-6090), 1988; 12(2): 69-75.
Impact Factor: 0.643
Dettagli Esporta in BibTeX Esporta in EndNote
Alfano B, Coucourde F, Malgieri F, Ragozzino A
PET/CT and radiotherapy (1692 visite)
Q J Nucl Med Mol Imaging, 1980 Oct; 50(1): 4-14.
Impact Factor: 0
Dettagli Esporta in BibTeX Esporta in EndNote
96 Records (74 escludendo Abstract e Conferenze).
Impact factor totale: 339.037 (269.355 escludendo Abstract e Conferenze).
Impact factor a 5 anni totale: 356.198 (267.812 escludendo Abstract e Conferenze).
Impact factor totale: 339.037 (269.355 escludendo Abstract e Conferenze).
Impact factor a 5 anni totale: 356.198 (267.812 escludendo Abstract e Conferenze).
Esporta in BibTeX Esporta in EndNote
Ultima modifica di Marco Comerci in data Thursday 19 March 2015, 16:43:14
290 visite. Ultima visita in data Friday 26 June 2020, 5:03:41
ibb.cnr.it